タイトル | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. |
---|
ジャーナル・号・ページ | Nat Commun, Vol. 14, Page 3079-3079, Year 2023 |
---|
掲載日 | 2022年4月7日 (構造データの登録日) |
---|
著者 | Saez-Ayala, M. / Hoffer, L. / Abel, S. / Ben Yaala, K. / Sicard, B. / Andrieu, G.P. / Latiri, M. / Davison, E.K. / Ciufolini, M.A. / Bremond, P. ...Saez-Ayala, M. / Hoffer, L. / Abel, S. / Ben Yaala, K. / Sicard, B. / Andrieu, G.P. / Latiri, M. / Davison, E.K. / Ciufolini, M.A. / Bremond, P. / Rebuffet, E. / Roche, P. / Derviaux, C. / Voisset, E. / Montersino, C. / Castellano, R. / Collette, Y. / Asnafi, V. / Betzi, S. / Dubreuil, P. / Combes, S. / Morelli, X. |
---|
リンク | Nat Commun / PubMed:37248212 |
---|
手法 | X線回折 |
---|
解像度 | 1.7 - 2.18 Å |
---|
構造データ | PDB-7zi1: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi1 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.85 Å PDB-7zi2: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi2 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 2.18 Å PDB-7zi3: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0642 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.9 Å PDB-7zi5: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0274 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 2 Å PDB-7zi6: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0325 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 2.1 Å PDB-7zi7: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0345 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-7zi8: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0602 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.99 Å PDB-7zi9: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0624 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-7zia: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0634 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.7 Å PDB-7zib: Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0635 inhibitor 手法: X-RAY DIFFRACTION / 解像度: 1.95 Å |
---|
化合物 | ChemComp-JCA: N-[3-[[4-(4-azanylpyrimidin-2-yl)-1,3-thiazol-2-yl]amino]-4-methyl-phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide
ChemComp-J7W: N-[3-[[4-[4,6-bis(azanyl)pyrimidin-2-yl]-1,3-thiazol-2-yl]amino]-4-methyl-phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide
ChemComp-J98: 2-[2-[[2-methyl-5-[4-(4-methylpiperazin-1-yl)sulfonyl-2-(trifluoromethyl)phenyl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine
ChemComp-J9I: 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]phenyl]-1,3-thiazol-2-amine
ChemComp-JAQ: 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]phenyl]-1,3-thiazol-2-amine
ChemComp-JCM: 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]phenyl]-N-propyl-1,3-thiazol-2-amine
ChemComp-J5U: 2-[2-[[2-methyl-5-[6-[2-(4-methylpiperazin-1-yl)ethyl]pyridin-3-yl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine
ChemComp-J6M: 2-[2-[[2-methyl-5-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine
ChemComp-J29: 2-[2-[[2-methyl-5-[6-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine
ChemComp-J7I: 2-[2-[[5-[3-methoxy-4-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-2-methyl-phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine
|
---|
由来 | homo sapiens (ヒト)
|
---|
キーワード | TRANSFERASE / Inhibitor |
---|